Symbols / TLX Stock $10.19 -1.36% Telix Pharmaceuticals Limited

Healthcare • Biotechnology • Australia • NMS
TLX (Stock) Chart
O: — H: — L: — C: — V: —
SMA 20: — SMA 50: — SMA 200: —
About

Telix Pharmaceuticals Limited, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals. The company operates through three segments: Precision Medicine, Therapeutics, and Manufacturing Solutions. Its lead therapeutic product candidate is TLX591, a lutetium-labeled radio antibody-drug conjugate (rADC), which is in a Phase 3 clinical trial in patients with advanced prostate cancer. The company develops TLX250, an rADC for treating advanced metastatic kidney cancer; TLX101, a systemic therapy for the treatment of glioblastoma; TLX66, a product candidate for bone marrow conditioning for hematopoietic stem cell transplant conditioning; and Illuccix and Gozellix for the treatment of prostate cancer. The company is also developing TLX592, a prostate cancer therapy candidate for targeted alpha therapy based on its proprietary RADmAb-engineered antibody technology; TLX252 for the treatment of patients with advanced metastatic kidney cancer; TLX400, a bladder fibroblast activation protein for treating various tumors; TLX102, a large amino acid transporter-targeting small molecule-based alpha therapy candidate for the treatment of glioblastoma and multiple myeloma; TLX300 for treating soft tissue sarcoma; and TLX090, a bone-seeking agent for bone metastases and pain palliation. In addition, it is developing BiPASS, which is in Phase 3 clinical trial for prostate cancer diagnosis; AlFluor, a novel PET radiochemistry solution; TLX250-Px, a PET diagnostic imaging agent; and TLX101-Px, a radiolabeled amino acid PET agent. It operates in Australia, Belgium, Canada, the United Kingdom, the United States, and internationally. The company has strategic collaboration with University Hospital Essen. The company was founded in 2015 and is headquartered in North Melbourne, Australia.

Stock Fundamentals
Scroll to Statements
Market Cap 3.45B Enterprise Value 3.82B Income -7.12M Sales 803.79M Book/sh 1.23 Cash/sh 0.42
Dividend Yield — Payout 0.00% Employees 1120 IPO — P/E — Forward P/E 41.34
PEG — P/S 4.29 P/B 8.31 P/C — EV/EBITDA 117.83 EV/Sales 4.76
Quick Ratio 1.21 Current Ratio 1.43 Debt/Eq 112.45 LT Debt/Eq — EPS (ttm) -0.02 EPS next Y 0.25
EPS Growth — Revenue Growth 49.30% Earnings — ROA 1.15% ROE -1.86% ROIC —
Gross Margin 47.50% Oper. Margin 1.94% Profit Margin -0.89% Shs Outstand 338.78M Shs Float 272.63M Short Float 0.10%
Short Ratio 1.09 Short Interest — 52W High 20.00 52W Low 6.28 Beta 0.61 Avg Volume 265.90K
Volume 133.10K Target Price $21.53 Recom Strong_buy Prev Close $10.33 Price $10.19 Change -1.36%
Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
$21.53
Mean price target
2. Current target
$10.19
Latest analyst target
3. DCF / Fair value
$-1.95
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$10.19
Low
$20.12
High
$22.72
Mean
$21.53

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2026-04-13 reit Wedbush Outperform → Outperform $22
2026-04-13 reit HC Wainwright & Co. Buy → Buy $20
2026-04-07 reit Wedbush Outperform → Outperform $22
2026-04-07 reit HC Wainwright & Co. Buy → Buy $20
2026-02-24 main Citigroup Buy → Buy $23
2026-01-21 reit HC Wainwright & Co. Buy → Buy $20
2025-12-22 reit HC Wainwright & Co. Buy → Buy $20
2025-09-23 main UBS Buy → Buy $20
2025-09-18 init Citigroup — → Buy $22
2025-09-10 main HC Wainwright & Co. Buy → Buy $20
2025-08-28 down JP Morgan Overweight → Neutral —
2025-08-28 reit Wedbush Outperform → Outperform $22
2025-07-03 init HC Wainwright & Co. — → Buy $23
2025-06-12 reit Wedbush Outperform → Outperform $22
2025-06-05 init Wedbush — → Outperform $22
2025-01-27 main UBS Buy → Buy $22
2024-11-15 init UBS — → Buy $21
News
RSS: Latest TLX news
Insider Transactions

No recent insider transactions.

Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Revenue
803.79
+55.61%
516.55
+55.13%
332.98
+205.73%
108.91
Operating Revenue
803.79
+55.61%
516.55
+55.13%
332.98
+205.73%
108.91
Cost Of Revenue
377.36
+109.19%
180.39
+46.13%
123.44
+178.44%
44.34
Reconciled Cost Of Revenue
377.36
+109.19%
180.39
+46.13%
123.44
+178.44%
44.34
Gross Profit
426.44
+26.85%
336.16
+60.43%
209.53
+224.46%
64.58
Operating Expense
408.38
+45.55%
280.58
+60.73%
174.57
+51.73%
115.05
Research And Development
171.25
+33.86%
127.93
+49.95%
85.31
+55.43%
54.89
Selling General And Administration
237.15
+55.82%
152.19
+70.27%
89.38
+50.30%
59.47
Selling And Marketing Expense
141.36
+94.65%
72.62
+82.86%
39.72
+35.83%
29.24
General And Administrative Expense
95.79
+20.39%
79.57
+60.20%
49.67
+64.29%
30.23
Salaries And Wages
—
—
—
64.48
Other Gand A
91.24
+18.90%
76.73
+62.71%
47.16
+63.72%
28.80
Other Operating Expenses
-0.01
-102.62%
0.46
+452.31%
-0.13
-118.79%
0.69
Total Expenses
785.74
+70.45%
460.97
+54.68%
298.01
+86.97%
159.39
Operating Income
18.05
-67.52%
55.58
+58.97%
34.97
+169.27%
-50.48
Total Operating Income As Reported
29.78
-46.04%
55.18
+401.24%
11.01
+111.97%
-91.93
EBITDA
35.15
-43.37%
62.06
+437.96%
11.54
+118.43%
-62.60
Normalized EBITDA
24.66
-60.71%
62.77
+76.78%
35.51
+170.36%
-50.47
Reconciled Depreciation
—
—
6.74
+84.27%
3.66
EBIT
35.15
-43.37%
62.06
+437.96%
11.54
+118.43%
-62.60
Total Unusual Items
10.49
+1585.69%
-0.71
+97.05%
-23.97
-97.68%
-12.13
Total Unusual Items Excluding Goodwill
10.49
+1585.69%
-0.71
+97.05%
-23.97
-97.68%
-12.13
Special Income Charges
11.05
+187.71%
-12.60
+45.77%
-23.24
-104.45%
-11.37
Impairment Of Capital Assets
0.57
+219.16%
-0.47
-186.36%
0.55
0.00
Restructuring And Mergern Acquisition
-11.62
-188.85%
13.08
-42.36%
22.69
+99.61%
11.37
Net Income
-7.12
-121.15%
33.69
+700.50%
4.21
+104.04%
-104.08
Pretax Income
-5.27
-113.89%
37.91
+1361.64%
2.59
+102.63%
-98.62
Net Non Operating Interest Income Expense
-35.04
-103.00%
-17.26
-105.16%
-8.41
-84.82%
-4.55
Interest Expense Non Operating
40.42
+67.35%
24.15
+170.04%
8.94
+98.88%
4.50
Net Interest Income
-35.04
-103.00%
-17.26
-105.16%
-8.41
-25.73%
-6.69
Interest Expense
40.42
+67.35%
24.15
+170.04%
8.94
+98.88%
4.50
Interest Income Non Operating
5.83
-18.86%
7.18
+970.04%
0.67
+67000.00%
0.00
Interest Income
5.83
-18.86%
7.18
+970.04%
0.67
+67000.00%
0.00
Other Income Expense
11.72
+2980.34%
-0.41
+98.30%
-23.96
-98.58%
-12.06
Other Non Operating Income Expenses
1.23
+312.71%
0.30
+2035.71%
0.01
-77.39%
0.06
Gain On Sale Of Security
-0.56
-104.73%
11.89
+1720.57%
-0.73
+3.49%
-0.76
Tax Provision
1.86
-56.05%
4.23
+362.08%
-1.61
-129.58%
5.46
Tax Rate For Calcs
0.00
+168.90%
0.00
-62.81%
0.00
+0.00%
0.00
Tax Effect Of Unusual Items
3.15
+4095.04%
-0.08
+98.90%
-7.19
-97.68%
-3.64
Net Income Including Noncontrolling Interests
-7.12
-121.15%
33.69
+700.50%
4.21
+105.94%
-70.80
Net Income From Continuing Operation Net Minority Interest
-7.12
-121.15%
33.69
+700.50%
4.21
+105.94%
-70.80
Net Income From Continuing And Discontinued Operation
-7.12
-121.15%
33.69
+700.50%
4.21
+105.94%
-70.80
Net Income Continuous Operations
-7.12
-121.15%
33.69
+700.50%
4.21
+104.04%
-104.08
Normalized Income
-14.47
-142.16%
34.31
+63.49%
20.99
+133.68%
-62.32
Net Income Common Stockholders
-7.12
-121.15%
33.69
+700.50%
4.21
+104.04%
-104.08
Diluted EPS
-0.02
-121.62%
0.10
+789.78%
0.01
+103.27%
-0.34
Basic EPS
-0.02
-120.75%
0.10
+827.16%
0.01
+104.81%
-0.23
Basic Average Shares
319.18
-3.64%
331.23
+3.77%
319.18
+2.75%
310.64
Diluted Average Shares
323.71
-6.22%
345.19
+8.15%
319.18
+2.75%
310.64
Diluted NI Availto Com Stockholders
-7.12
-121.15%
33.69
+700.50%
4.21
+104.04%
-104.08
Amortization
—
—
4.34
+6.00%
4.10
Amortization Of Intangibles Income Statement
—
—
4.34
+55.82%
2.79
Depreciation Amortization Depletion Income Statement
—
—
6.74
+25.36%
5.38
Depreciation And Amortization In Income Statement
—
—
6.74
+84.27%
3.66
Depreciation Income Statement
—
—
2.40
+175.28%
0.87
Rent And Landing Fees
—
—
2.32
—
Rent Expense Supplemental
4.55
+60.49%
2.83
+12.99%
2.51
+75.87%
1.43
Total Other Finance Cost
0.45
+54.79%
0.29
+105.63%
0.14
+151.48%
0.06
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Assets
1,163.99
+23.78%
940.38
+239.17%
277.26
+59.60%
173.72
Current Assets
330.28
-42.07%
570.12
+259.26%
158.69
-8.39%
173.23
Cash Cash Equivalents And Short Term Investments
141.87
-67.76%
440.00
+421.98%
84.30
-27.54%
116.33
Cash And Cash Equivalents
141.87
-67.76%
440.00
+421.98%
84.30
-27.54%
116.33
Cash Financial
—
—
123.24
+5.94%
116.33
Receivables
138.37
+38.85%
99.65
+102.23%
49.28
+25.22%
39.35
Accounts Receivable
129.20
+48.63%
86.93
+97.38%
44.04
+11.91%
39.35
Gross Accounts Receivable
131.58
+51.14%
87.06
+95.66%
44.50
+13.07%
39.35
Allowance For Doubtful Accounts Receivable
-2.38
-1714.50%
-0.13
+63.93%
-0.36
—
Other Receivables
1.29
-27.22%
1.77
+9.76%
1.61
—
Taxes Receivable
7.88
-28.07%
10.96
+109.26%
5.24
—
Inventory
37.08
+56.99%
23.62
+85.43%
12.74
+50.27%
8.48
Raw Materials
18.73
+110.14%
8.91
+15.78%
7.70
+367.32%
1.65
Work In Process
9.79
+13.85%
8.60
+44.24%
5.96
+57.99%
3.77
Finished Goods
25.41
+192.57%
8.69
+249.39%
2.49
+60.14%
1.55
Prepaid Assets
12.96
+89.41%
6.84
-19.13%
8.46
+396.02%
1.71
Other Current Assets
—
—
12.38
+88.58%
6.57
Total Non Current Assets
833.71
+125.17%
370.26
+212.28%
118.57
+44.38%
82.12
Net PPE
115.61
+243.61%
33.65
+61.31%
20.86
+10.72%
18.84
Gross PPE
133.53
+229.48%
40.53
+94.30%
20.86
+38.03%
15.11
Accumulated Depreciation
-17.92
-160.37%
-6.88
-73.66%
-3.96
-17.41%
-3.38
Properties
0.00
0.00
0.00
-100.00%
9.83
Land And Improvements
18.85
+57.84%
11.95
-15.51%
14.14
+43.83%
9.83
Machinery Furniture Equipment
35.08
+269.18%
9.50
+197.34%
3.20
+87.52%
1.70
Construction In Progress
12.44
+31.51%
9.46
—
—
Other Properties
—
—
20.86
+235.52%
6.22
Leases
67.16
+598.08%
9.62
+29.94%
7.40
+606.23%
1.05
Goodwill And Other Intangible Assets
592.82
+129.90%
257.86
+243.56%
75.05
+27.24%
58.98
Goodwill
198.99
+198.84%
66.59
+1916.37%
3.30
-12.05%
3.75
Other Intangible Assets
393.83
+105.90%
191.27
+82.48%
104.82
+188.18%
36.37
Investments And Advances
3.68
-2.54%
3.77
-55.00%
8.39
—
Long Term Equity Investment
3.68
-2.54%
3.77
-41.67%
6.47
—
Other Investments
—
—
12.26
—
Non Current Accounts Receivable
1.34
—
0.59
+79.20%
0.33
Non Current Deferred Assets
59.35
+105.23%
28.92
+106.70%
13.99
+252.33%
3.97
Non Current Deferred Taxes Assets
59.35
+105.23%
28.92
+106.70%
13.99
+252.33%
3.97
Other Non Current Assets
60.90
+32.21%
46.06
+16529.60%
0.28
—
Total Liabilities Net Minority Interest
748.61
+27.44%
587.44
+236.43%
174.61
-0.42%
175.35
Current Liabilities
231.62
+12.94%
205.09
+84.15%
111.37
+91.35%
58.20
Payables And Accrued Expenses
170.02
+45.47%
116.88
+73.29%
67.44
+36.20%
49.52
Payables
137.41
+63.93%
83.83
+24.29%
67.44
+100.20%
33.69
Accounts Payable
88.81
+78.77%
49.68
+51.28%
32.84
+95.39%
16.81
Other Payable
17.86
+339.89%
4.06
-92.53%
54.33
+66.09%
32.71
Current Accrued Expenses
32.61
-1.34%
33.05
+15.51%
28.61
—
Employee Benefits
0.44
+45.57%
0.30
+43.87%
0.21
-1.40%
0.21
Pensionand Other Post Retirement Benefit Plans Current
19.37
+36.96%
14.14
+48.45%
9.53
+26.18%
7.55
Total Tax Payable
30.74
+2.18%
30.09
+129.50%
13.11
—
Current Debt And Capital Lease Obligation
18.66
+40.19%
13.31
+1147.33%
1.07
+66.46%
0.64
Current Debt
13.11
+11.45%
11.76
+1682.27%
0.66
—
Other Current Borrowings
13.11
+11.45%
11.76
+1682.27%
0.66
—
Current Capital Lease Obligation
5.55
+258.86%
1.55
+279.85%
0.41
-36.51%
0.64
Current Deferred Liabilities
11.47
+64.63%
6.97
-7.38%
7.52
+2.76%
7.32
Current Deferred Revenue
0.40
-94.23%
6.97
-7.38%
7.52
—
Other Current Liabilities
11.54
-78.31%
53.22
+109.37%
25.42
+656.30%
3.36
Total Non Current Liabilities Net Minority Interest
516.99
+35.21%
382.35
+504.61%
63.24
-29.57%
89.79
Long Term Debt And Capital Lease Obligation
448.45
+29.29%
346.85
+2997.73%
11.20
+67.86%
6.67
Long Term Debt
391.91
+14.66%
341.81
+5649.55%
5.95
+163.85%
2.25
Long Term Capital Lease Obligation
56.53
+1021.26%
5.04
-4.00%
5.25
+18.90%
4.42
Long Term Provisions
9.18
+7.58%
8.53
+55.80%
5.47
-90.44%
57.25
Non Current Pension And Other Postretirement Benefit Plans
—
—
0.33
+53.49%
0.21
Non Current Deferred Liabilities
44.71
+470.81%
7.83
-5.87%
8.32
—
Non Current Deferred Revenue
0.00
-100.00%
2.04
-75.53%
8.32
—
Non Current Deferred Taxes Liabilities
44.71
+671.33%
5.80
0.00
—
Other Non Current Liabilities
14.21
-24.55%
18.83
-50.48%
38.04
+68.88%
22.52
Stockholders Equity
415.38
+17.69%
352.94
+243.84%
102.64
+88.59%
54.43
Common Stock Equity
415.38
+17.69%
352.94
+243.84%
102.64
+28.30%
80.01
Capital Stock
0.00
0.00
0.00
-100.00%
252.37
Common Stock
0.00
0.00
0.00
-100.00%
370.97
Share Issued
338.78
+1.21%
334.72
+3.40%
323.73
+2.33%
316.34
Ordinary Shares Number
338.78
+1.21%
334.72
+3.40%
323.73
+2.33%
316.34
Additional Paid In Capital
479.96
+15.93%
414.01
+31.36%
315.18
—
Retained Earnings
-154.54
-1.06%
-152.91
+18.28%
-187.12
+31.41%
-272.81
Gains Losses Not Affecting Retained Earnings
89.95
-2.05%
91.84
+461.37%
-25.41
-105.82%
-12.35
Other Equity Adjustments
89.95
-2.05%
91.84
+461.37%
-25.41
-112.40%
-11.97
Total Equity Gross Minority Interest
415.38
+17.69%
352.94
+243.84%
102.64
+88.59%
54.43
Total Capitalization
807.29
+16.20%
694.75
+539.79%
108.59
+91.58%
56.68
Working Capital
98.66
-72.97%
365.03
+671.44%
47.32
-46.03%
87.68
Invested Capital
820.40
+16.12%
706.51
+546.69%
109.25
+31.12%
83.32
Total Debt
467.11
+29.69%
360.16
+2836.74%
12.26
+17.40%
10.45
Net Debt
263.16
—
—
—
Capital Lease Obligations
62.08
+842.35%
6.59
+16.42%
5.66
+16.60%
4.85
Net Tangible Assets
-177.45
-286.63%
95.08
+244.60%
27.59
+92.92%
14.30
Tangible Book Value
-177.45
-286.63%
95.08
+244.60%
27.59
+31.24%
21.02
Available For Sale Securities
—
—
8.39
—
Current Deferred Taxes Liabilities
—
—
11.51
+57.21%
7.32
Current Provisions
0.56
-2.43%
0.58
+45.82%
0.40
-96.27%
10.60
Foreign Currency Translation Adjustments
—
—
-68.24
-12042.88%
-0.56
Inventories Adjustments Allowances
-16.86
-553.59%
-2.58
0.00
—
Investmentin Financial Assets
—
0.00
-100.00%
8.39
—
Investments In Other Ventures Under Equity Method
3.68
-2.54%
3.77
-60.26%
9.50
—
Investmentsin Associatesat Cost
—
2.70
0.00
—
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Investing Cash Flow
-285.92
-229.83%
-86.69
-414.80%
-16.84
+0.93%
-17.00
Cash Flow From Continuing Investing Activities
-285.92
-229.83%
-86.69
-414.80%
-16.84
-45.63%
-11.56
Net PPE Purchase And Sale
-25.69
-181.80%
-9.12
-44.55%
-6.31
+10.39%
-7.04
Purchase Of PPE
-25.69
-181.80%
-9.12
-44.55%
-6.31
+10.39%
-7.04
Capital Expenditure
-43.78
-97.33%
-22.18
-212.06%
-7.11
+24.61%
-9.43
Net Investment Purchase And Sale
-0.89
+97.29%
-32.91
-278.40%
-8.70
0.00
Purchase Of Investment
-0.89
+97.29%
-32.91
-278.40%
-8.70
0.00
Net Business Purchase And Sale
-229.03
-887.41%
-23.20
-2231.16%
-0.99
-2.26%
-0.97
Purchase Of Business
-229.03
-887.41%
-23.20
-2231.16%
-0.99
-2.26%
-0.97
Net Intangibles Purchase And Sale
-18.08
-38.39%
-13.07
-1529.30%
-0.80
+82.72%
-4.64
Purchase Of Intangibles
-18.08
-38.39%
-13.07
-1529.30%
-0.80
+88.25%
-6.82
Net Other Investing Changes
-12.22
-45.61%
-8.39
-22589.19%
-0.04
+97.49%
-1.47
Financing Cash Flow
-3.72
-100.89%
416.79
+5777.75%
7.09
-94.04%
119.03
Cash Flow From Continuing Financing Activities
-3.72
-100.89%
416.79
+5777.75%
7.09
-95.95%
174.96
Net Issuance Payments Of Debt
-5.53
-101.30%
425.84
+14473.65%
2.92
+68.22%
1.74
Issuance Of Debt
0.53
-99.88%
427.90
+10117.38%
4.19
+38.95%
3.01
Repayment Of Debt
-6.06
-193.70%
-2.06
-62.88%
-1.27
-45.73%
-0.87
Long Term Debt Issuance
0.53
-99.88%
427.90
+10117.38%
4.19
+104.25%
2.05
Long Term Debt Payments
-6.06
-193.70%
-2.06
-62.88%
-1.27
-45.73%
-0.87
Net Long Term Debt Issuance
-5.53
-101.30%
425.84
+14473.65%
2.92
+68.22%
1.74
Net Common Stock Issuance
1.81
+173.11%
0.66
-84.12%
4.17
-97.70%
181.04
Common Stock Payments
—
—
—
-7.82
Repurchase Of Capital Stock
—
—
—
-7.82
Net Other Financing Charges
—
-9.71
-337.13%
-2.22
+58.21%
-5.32
Changes In Cash
-306.93
-185.83%
357.59
+7802.63%
4.53
-95.19%
93.99
Effect Of Exchange Rate Changes
8.80
+565.61%
-1.89
-290.52%
0.99
+231.77%
0.30
Beginning Cash Position
440.00
+421.98%
84.30
+7.00%
78.78
+257.48%
22.04
End Cash Position
141.87
-67.76%
440.00
+421.98%
84.30
+6.52%
79.14
Free Cash Flow
-61.07
-1250.94%
5.31
-25.94%
7.16
+109.20%
-77.83
Interest Paid Supplemental Data
—
—
0.79
+499.24%
0.13
Income Tax Paid Supplemental Data
—
—
10.25
+350.09%
2.28
Cash Flowsfromusedin Operating Activities Direct
-17.29
-162.91%
27.49
+92.60%
14.27
+122.31%
-63.97
Classesof Cash Payments
-783.63
-76.39%
-444.26
-49.00%
-298.16
-112.17%
-140.53
Classesof Cash Receiptsfrom Operating Activities
774.20
+65.55%
467.66
+50.01%
311.75
+220.45%
97.29
Common Stock Issuance
1.81
+173.11%
0.66
-84.12%
4.17
-97.70%
181.04
Interest Paid Direct
-13.70
-343.80%
-3.09
-701.82%
-0.39
-38.71%
-0.28
Interest Received Direct
5.84
-18.62%
7.18
+572.28%
1.07
+106700.00%
0.00
Issuance Of Capital Stock
1.81
+173.11%
0.66
-84.12%
4.17
-97.70%
181.04
Other Cash Paymentsfrom Operating Activities
-51.79
-116.66%
-23.90
-118.94%
-10.92
—
Other Cash Receiptsfrom Operating Activities
—
—
-16.28
-186.11%
18.91
Paymentsto Suppliersfor Goodsand Services
-710.55
-69.85%
-418.33
-49.20%
-280.39
-101.75%
-138.98
Receiptsfrom Customers
774.20
+65.55%
467.66
+50.01%
311.75
+269.28%
84.42
Taxes Refund Paid Direct
-21.30
-947.61%
-2.03
+70.36%
-6.86
-160.62%
11.31
SEC Filings

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category